---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-036647"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T09:17:58.351900+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Windtree engages New Growth Advisors to explore strategic options for cardiovascular portfolio

## Summary
- Engaged New Growth Advisors to lead out-licensing or asset sale process for istaroxime and oral SERCA2a activators.
- Company cites positive Phase 2b SEISMiC study in early cardiogenic shock as catalyst for potential non-dilutive partnership.
- Existing Lee's Pharmaceuticals deal offers up to $138M in milestones plus low double-digit royalties for Greater China.
- NGA has advised on transactions with aggregate value approaching $400M from 2023 through 2024.
- Proceeds from any deal would support advancement of Windtree's novel preclinical oncology platform.

## SEC filing metadata
- accession: 0001437749-24-036647
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924036647/0001437749-24-036647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924036647/wint20241202_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-036647
- JSON: https://secwatch.observer/filing/0001437749-24-036647.json
- Plain text: https://secwatch.observer/filing/0001437749-24-036647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.